
## Nagham J Ailabouni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5617727/publications.pdf Version: 2024-02-01



NACHAM LAHABOUNI

#	Article	IF	CITATIONS
1	Leveraging implementation science to increase the translation of deprescribing evidence into practice. Research in Social and Administrative Pharmacy, 2022, 18, 2550-2555.	3.0	22
2	Barriers and enablers of older adults initiating a deprescribing conversation. Patient Education and Counseling, 2022, 105, 615-624.	2.2	15
3	Considerations for systematic reviews of quantitative surveys: Learnings from a systematic review of the Patients' Attitudes Towards Deprescribing questionnaire. Research in Social and Administrative Pharmacy, 2022, 18, 2345-2349.	3.0	4
4	Consumer Attitudes Towards Deprescribing: A Systematic Review and Meta-Analysis. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 1020-1034.	3.6	45
5	COVID-19 Pandemic: Considerations for Safe Medication Use in Older Adults with Multimorbidity and Polypharmacy. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 1068-1073.	3.6	20
6	Alterations in drug disposition in older adults: a focus on geriatric syndromes. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 41-52.	3.3	33
7	Difficulty with Taking Medications Is Associated with Future Diagnosis of Alzheimer's Disease and Related Dementias. Journal of General Internal Medicine, 2021, 36, 863-868.	2.6	5
8	Medication Use Quality and Safety in Older Adults: 2019 Update. Journal of the American Geriatrics Society, 2021, 69, 336-341.	2.6	4
9	Deprescribing to reduce polypharmacy: study protocol for a randomised controlled trial assessing deprescribing of anticholinergic and sedative drugs in a cohort of frail older people living in the community. Trials, 2021, 22, 766.	1.6	3
10	Can existing tools predict older adults' willingness to deprescribe? Considerations for D-PRESCRIBE's post-hoc secondary analysis. Research in Social and Administrative Pharmacy, 2019, 15, 1379-1380.	3.0	6
11	DEFEAT-polypharmacy: deprescribing anticholinergic and sedative medicines feasibility trial in residential aged care facilities. International Journal of Clinical Pharmacy, 2019, 41, 167-178.	2.1	70
12	Medication Use Quality and Safety in Older Adults: 2018 Update. Journal of the American Geriatrics Society, 2019, 67, 2458-2462.	2.6	4
13	Deprescribing anticholinergic and sedative medicines: protocol for a Feasibility Trial (DEFEAT-polypharmacy) in residential aged care facilities. BMJ Open, 2017, 7, e013800.	1.9	20
14	Do Residents Need All Their Medications? A Cross-Sectional Survey of RNs' Views on Deprescribing and the Role of Clinical Pharmacists. Journal of Gerontological Nursing, 2017, 43, 13-20.	0.6	12
15	General practitioners' insight into deprescribing for the multimorbid older individual: a qualitative study. International Journal of Clinical Practice, 2016, 70, 261-276.	1.7	48
16	Improvements in the prescribing of antipsychotics in dementia and psychogeriatric units in New Zealand. International Journal of Clinical Pharmacy, 2016, 38, 941-949.	2.1	7
17	Examining potentially inappropriate prescribing in residential care using the STOPP/START criteria. European Geriatric Medicine, 2016, 7, 40-46.	2.8	10
18	Challenges and Enablers of Deprescribing: A General Practitioner Perspective. PLoS ONE, 2016, 11, e0151066.	2.5	148